Suven Life Sciences Ltd has secured four product patents for its new chemical entities associated with neurodegenerative diseases. They include one each from Japan, Australia, Europe and Eurasia and are valid till 2024 and 2027, the Hyderabad-based company said in a release.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and were being developed as therapeutic agents for the treatment of neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia. With these, Suven now has a total of five granted patents from Japan, 14 from Australia, 12 from Europe and 10 from Eurasia.